Is there still a place for docetaxel rechallenge in prostate cancer?

doi:10.5306/wjco.v6.i5.99

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6606)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

402

WORD

289

HTML

2831

Tables (1-1)

189

Sum=3711

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1047

Download

1848

Sum=2895

Oct 10, 2015 (publication date) through Aug 31, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Oct 10, 2015; 6(5): 99-103
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.99

Table 1 Main eligibility criteria for docetaxel rechallenge in metastatic castrate-resistant prostate cancer patients

PFI > 3-6 mo

> 50% PSA response to first-line docetaxel

No cumulative docetaxel-toxicity

Age < 75 yr

ECOG PS 0-1

PFI: Progression free-interval; PSA: Prostatic-specific antigen.

Citation: Petrioli R, Francini E, Roviello G. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 2015; 6(5): 99-103
URL: https://www.wjgnet.com/2218-4333/full/v6/i5/99.htm
DOI: https://dx.doi.org/10.5306/wjco.v6.i5.99